Companies Dominating the Radiotheranostics Landscape
- TransCode Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Clarity Pharmaceuticals
- Ariceum Therapeutics GmbH
- Novartis AG
- Bayer AG
- Progenics Pharmaceuticals, Inc.
- Telix Pharmacuticals Limited
- ITM Radiopharma
- Life Molecular Imaging
- RadioMedix
- Hitachi, Ltd.
- Chiba University
- Shimadzu Corporation
- Canon Medical System Corporation
- Toshiba Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Radiotheranostics Market in 2025 is estimated at USD 2.59 billion.
The global market size was valued at over USD 2.32 billion in 2024 and is expected to expand at a CAGR of over 14.6%, surpassing USD 13.64 billion revenue by 2037.
North America is forecast to hit USD 4.09 billion by 2037, attributed to rising use of imaging technologies and precision medicine.
The major players in the market include Clarity Pharmaceuticals, Ariceum Therapeutics GmbH, Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc., Telix Pharmacuticals Limited, ITM Radiopharma.
